<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05102747</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A01622-39</org_study_id>
    <nct_id>NCT05102747</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.</brief_title>
  <acronym>OligoBM-01</acronym>
  <official_title>Stereotactic Radiotherapy in Oligometastatic Brain Disease: a Randomised Phase III Study Comparing Hypofractionated Stereotactic Radiation Therapy (3*10 Gy) to the Historical Single-dose Radiosurgery (1*20 to 25 Gy) With Medico-economic Evaluation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association de Neuro-Oncologues d'Expression Francaise</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain metastases (BM) are a common systemic cancer manifestation which incidence increases.&#xD;
      Therapeutic options include whole-brain radiotherapy (WBRT), surgery, and stereotactic&#xD;
      radiosurgery (SRS). The concept of &quot;oligometastatic&quot; cerebral disease (oligoBM) has emerged&#xD;
      and led to consider alternative approaches. The main challenge is to preserve neurological&#xD;
      function and independence the longest as possible.&#xD;
&#xD;
      Stereotactic radiotherapy (SRT) has emerged as an alternative treatment modality for selected&#xD;
      oligoBM patients. It allows to achieve the balance of tumour destruction and normal tissue&#xD;
      preservation by precisely and accurately delivering a very high dose of radiation in one&#xD;
      (SRS) or a few (HSRT) fractions to a limited, well-defined volume. However, no standard&#xD;
      exists for decision-making between SRS and HSRT and this important question is being&#xD;
      discussed in the recent literature.&#xD;
&#xD;
      HSRT appears particularly interesting, assuming the patient convenience of few fractions, the&#xD;
      normal tissue sparing achieved through focal irradiation, and the improved normal tissue&#xD;
      tolerance of high dose radiation through fractionation.&#xD;
&#xD;
      Common adverse effects of SRT are rare but can occasionally be serious, notably radionecrosis&#xD;
      that may induce neurological deficits in patients. Although SRS is often less well-tolerated,&#xD;
      it remains the mainstay of treatment.&#xD;
&#xD;
      To investigators knowledge, SRS and HSRT have not been prospectively compared.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Local control assessed by RANO-BM criteria</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain acute and late toxicities assessed by NCI CTCAE v5.0</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radionecrosis by RANO-BM criteria</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">504</enrollment>
  <condition>Brain Metastasis</condition>
  <condition>Oligoprogression</condition>
  <arm_group>
    <arm_group_label>Hypofractionated SRT (stereotactic radiotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Historical single-dose SRS (stereotactic radiosurgery)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated SRT (stereotactic radiotherapy)</intervention_name>
    <description>3*10Gy over 1 week</description>
    <arm_group_label>Hypofractionated SRT (stereotactic radiotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Historical single-dose SRS (stereotactic radiosurgery)</intervention_name>
    <description>20 to 25Gy/1 fraction</description>
    <arm_group_label>Historical single-dose SRS (stereotactic radiosurgery)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 years or older&#xD;
&#xD;
          -  WHO performance status 0 or 1;&#xD;
&#xD;
          -  Patient eligible for SRT after a multidisciplinary committee decision; Patient with&#xD;
             BMs from radioresistant cancer (renal cell carcinoma, sarcoma, melanoma) is eligible&#xD;
&#xD;
          -  Patient having up to 5 BM of solid tumours with an histologically proven diagnoses;&#xD;
             patients who have had a metastasectomy and having 1 to 4 BM lesions is eligible&#xD;
             (ANOCEF recommendations); post-operative cavity must be treated by radiosurgery&#xD;
             according to local procedures with respect of non-inclusion criteria* (cavity will not&#xD;
             be analyzed for efficacy)&#xD;
&#xD;
          -  Each targeted brain lesion(s) for SRT measuring at least 10 mm and no more than 25 mm&#xD;
             in diameter; patients whose synchronous 1-5 BM include 4 lesions measuring less than&#xD;
             10 mm and/or more than 25 mm will be eligible (these lesions will be treated at the&#xD;
             discretion of the investigator).&#xD;
&#xD;
          -  Max cumulative GTV of 30cm3&#xD;
&#xD;
          -  Patient with an extra-cranial complete response disease under systemic therapy&#xD;
             (chemotherapy or targeted therapy);&#xD;
&#xD;
          -  Patient with an extra-cranial partial response or stable disease for more than three&#xD;
             months under systemic therapy (chemotherapy or targeted therapy);&#xD;
&#xD;
          -  Absence of bleeding BM or meningeal carcinomatosis;&#xD;
&#xD;
          -  Symptomatic BM are allowed&#xD;
&#xD;
          -  DS-GPA score 0:&#xD;
&#xD;
               -  Renal cancer: DS-GPA 2,5 or more&#xD;
&#xD;
               -  Breast cancer: DS-GPA 2,5 or more&#xD;
&#xD;
               -  Melanoma: DSGPA 3 or more&#xD;
&#xD;
               -  Gastro-Instestinal (GI) cancer: DSGPA 3 or more&#xD;
&#xD;
               -  Adenocarcinoma lung cancer: DS-GPA 2 or more (DS-GPAmol)&#xD;
&#xD;
               -  Squamous lung cancer : DS-GPA 2,5 or more (DS-GPAmol)&#xD;
&#xD;
          -  Patient with no concomitant systemic treatment; in case of ongoing systemic treatment,&#xD;
             wash out period of 3-7 days before and after SRT, depending of drug and at the&#xD;
             discretion of investigator;&#xD;
&#xD;
          -  Patient sufficiently cooperating to perform the treatment with the use of a&#xD;
             thermoformed mask;&#xD;
&#xD;
          -  Patient whose neuropsychological abilities allow to follow the requirements of the&#xD;
             protocol;&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Patients affiliated to the social security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with small cell lung cancer, germ-cell tumours, lymphoma, leukemia and&#xD;
             multiple myeloma;&#xD;
&#xD;
          -  Patients with metastases in the brain stem, or within 1 cm of the optic apparatus;&#xD;
&#xD;
          -  Patients with an associated neurodegenerative disease;&#xD;
&#xD;
          -  Any symptoms not attributable to BM or cancer disease requiring long term&#xD;
             corticosteroid use (regardless of dose);&#xD;
&#xD;
          -  Contraindication to perform the brain MRI or gadolinium or iodinated contrast;&#xD;
&#xD;
          -  Patients with previous brain stereotactic irradiation&#xD;
&#xD;
          -  Whole brain irradiation history;&#xD;
&#xD;
          -  Progressive extra-cranial disease;&#xD;
&#xD;
          -  Haemorrhagic metastasis;&#xD;
&#xD;
          -  Ongoing anti angiogenic treatment (treatment should be held 3-7 days before&#xD;
             irradiation and re-initiated 3-7 days after irradiation for patient to be eligible);&#xD;
&#xD;
          -  Patients with too close brain lesions for whom a treatment plan on one target&#xD;
             metastasis delivers a dose &gt; 5 Gy on other concomitant metastasis ;&#xD;
&#xD;
          -  Patient deprived of liberty or under guardianship;&#xD;
&#xD;
          -  Known pregnancy or breastfeeding&#xD;
&#xD;
          -  Any geographical conditions, social and associated psychopathology that may compromise&#xD;
             the patient's ability to participate in the study;&#xD;
&#xD;
          -  Participation in a therapeutic trial for less than 30 days.&#xD;
&#xD;
          -  Current or past history of second neoplasm diagnosed within the last 5 years&#xD;
&#xD;
          -  Patient deprived of freedom or under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dinu STEFAN, MD</last_name>
    <phone>+33 (0)2 32 45 50 20</phone>
    <email>d.stefan@baclesse.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Michel GRELLARD</last_name>
    <phone>+33 (0)2 31 45 50 02</phone>
    <email>jm.grellard@baclesse.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Aymeri HUCHET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aymeri HUCHET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gurvan DISSAUX, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gurvan DISSAUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Dinu STEFAN, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jean-Michel GRELLARD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Dinu STEFAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Guillaume le Conquérant</name>
      <address>
        <city>Le Havre</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul LESUEUR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paul LESUEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Raphaelle MOUTTET AUDOUARD</last_name>
    </contact>
    <investigator>
      <last_name>Raphaelle MOUTTET AUDOUARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre Yves BONDIAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre Yves BONDIAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Julian JACOB, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julian JACOB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Khémara GNEP, MD</last_name>
    </contact>
    <investigator>
      <last_name>Khémara GNEP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Ovidiu VERESEZAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ovidiu VERESEZAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Frédéric DHERMAIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric DHERMAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stereotactic radiosurgery</keyword>
  <keyword>Fractionated stereotactic radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

